The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment;
however, the current dosing of the drug is not evidence based, and the optimal dosing is
unknown. Our objective was to conduct a preclinical evaluation of the pharmacokinetics and
pharmacodynamics of clofazimine in the mouse model of tuberculosis, with the goal of
providing useful information on dosing for future studies. Pharmacokinetic parameters were
evaluated in infected and uninfected BALB/c mice. Pharmacodynamic parameters were …

The anti-leprosy drug clofazimine has shown potential for shortening tuberculosis treatment;
22 however, the current dosing of this drug is not evidence-based, and the optimal dosing is
23 unknown. Our objective was to conduct a preclinical evaluation of the pharmacokinetics
and 24 pharmacodynamics of clofazimine in the mouse model of tuberculosis, with the goal
of 25 providing useful information on dosing for future studies. Pharmacokinetic parameters
were 26 evaluated in infected and uninfected BALB/c mice. Pharmacodynamic parameters …